OpenDNA and PartnerMD Announce Partnership to Deliver AI-Based Genetic Risk Testing for Cardiometabolic Diseases
OpenDNA, a leader in AI-driven precision medicine solutions, today announced a commercial partnership with PartnerMD, a concierge healthcare provider with facilities in Georgia, South Carolina, Maryland, and Virginia. Through this collaboration, PartnerMD patients will gain access to OpenDNA’s AI-based genetic risk testing to better understand and manage their cardiometabolic health. As one of the first […]
OpenDNA Announces Know-How & Research Agreement with Mayo Clinic for AI Cardiovascular Disease Prediction
OpenDNA, a provider of precision medicine AI platforms to predict and treat polygenic diseases, today announced a know-how and research agreement with Mayo Clinic as part of a pilot clinical study. The collaboration will evaluate OpenDNA’s technology for early AI cardiovascular disease prediction and its potential to support precision prevention and treatment strategies. Led by […]
OpenDNA Announces Successful Conclusion of 150-Patient Clinical Study on AI-Powered Cardiovascular Risk Prediction
OpenDNA, a leader in AI-based precision medicine, today announced the successful conclusion of a clinical study evaluating its AI-powered cardiovascular risk prediction platform. Conducted across three clinics in Maryland and New Jersey, the study enrolled 150 patients with diverse risk factors to assess the platform’s utilization, accuracy, and clinical impact. The study demonstrated the potential […]
Encore Concierge Medicine and OpenDNA Form Strategic Partnership to Deliver Advanced AI-Driven Genetic Risk Tests
Encore Concierge Medicine, a leader in personalized healthcare, today announced a strategic partnership with OpenDNA, an innovator in precision genomics, to provide patients with access to advanced AI-driven genetic risk tests. Through this collaboration, Encore Concierge Medicine will offer OpenDNA’s CardioRisk+, CancerRisk+, and TotalRisk+ tests, which combine polygenic and monogenic insights with clinical data to […]
OpenDNA Launches Next-Generation Genetic Risk Tests: PolyRisk+ and Extended TotalRisk+
OpenDNA has introduced two next-generation genetic risk tests designed to give physicians and patients a broader, more actionable picture of health risk: PolyRisk+, a polygenic risk score (PRS) panel, and an expanded TotalRisk+ test that integrates both polygenic and monogenic data with clinical information. Together, these new offerings extend coverage to 30 conditions across eight […]
Long-Term Study Highlights Genomics’ Power to Prevent Heart Attacks
A new post hoc 10–year follow–up analysis of the MI–GENES randomized clinical trial has found that disclosing a polygenic risk score (PRS) for coronary heart disease (CHD) may significantly reduce long–term cardiovascular events. The study followed 203 participants who were originally randomized to receive either a standard Framingham risk score (FRSg) or an integrated risk […]
OpenDNA Expands CardioRisk+ Genetic Testing Panel to Include Obesity Risk
OpenDNA, a leading provider of advanced genetic testing solutions, has announced the launch of a new genetic test for obesity, now available as part of its comprehensive CardioRisk+ panel. This enhancement provides healthcare professionals with critical insights into an individual’s genetic predisposition to obesity, supporting more targeted and proactive preventive care. CardioRisk+ is a state-of-the-art […]
OpenDNA and Mayo Clinic Present AI-Powered Heart Disease Risk Prediction Model at the American College of Cardiology
OpenDNA and Mayo Clinic presented a collaborative project at the American College of Cardiology (ACC) conference showcasing a new AI-powered model designed to predict coronary heart disease risk using polygenic risk scores (PRS). The study demonstrates the combined power of genetic and clinical data to support earlier, more personalized cardiovascular care. Researchers from Mayo Clinic […]
OpenDNA Launches TotalRisk+, a Revolutionary AI based Genetic Test for Cancer Screening
OpenDNA has officially launched TotalRisk+ – an advanced AI-based genetic test designed to assess an individual’s risk across multiple cancer types in a single analysis. This innovative solution is built on polygenic risk scores (PRS), combining the power of genomic data and machine learning to help identify those at elevated cancer risk earlier and more […]
Harper Health Partners with OpenDNA to Provide AI-Based Genetic Risk Testing
OpenDNA and Harper Health have announced a clinical partnership to provide AI-based genetic risk testing to patients across the U.S. The collaboration will integrate OpenDNA’s advanced polygenic risk score (PRS) technology into Harper Health’s personalized concierge care model. This collaboration will provide Harper Health patients with valuable insights into their risk for cardiovascular disease, cancer, […]